Sentiment Summary
Recent Events
The Annual General Meeting of shareholders is scheduled for 2026-06-16.
Ex-dividend date (2026-06-08) for a quarterly cash dividend of $0.22 per share, representing a 5% increase from the prior dividend. The dividend was declared on April 27, 2026 and is payable on June 15, 2026. A 1-2% price impact is estimated as dividend increases are generally viewed positively by the market, scheduled.
Medtronic will report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026, scheduled. High importance is estimated due to the significant market impact typically associated with annual earnings reports.
Publication of the full-year results for the 2025/26 financial year is scheduled. High importance is assigned as annual results typically drive significant market volatility.
An earnings briefing for the 2025 fiscal year and Q1 2026 results is scheduled for May 14, 2026. This routine communication event is estimated to have a price impact of at least 1% scheduled.
First quarter 2026 financial results are scheduled to be released after market close on May 11, 2026, scheduled; high importance as earnings releases typically result in price movements exceeding 10%.
Medium importance estimated as earnings typically cause 5-10% volatility; Q1 2026 financial results release on May 7, 2026, with analysts forecast of revenue of $740.34 million and EPS of $0.92 scheduled.
Q2 2025/26 earnings release is scheduled. Earnings announcements typically drive moderate price volatility of approximately 5%.
LivaNova to announce its first-quarter 2026 financial results on May 6, 2026, scheduled. Medium importance as earnings releases typically cause significant volatility (estimated ≥5% impact).
Inspire Medical Systems is scheduled to release its financial results for the first quarter of 2026 after the market closes on May 4, 2026. Analysts forecast earnings per share of approximately -$0.34 and revenue of $201.04 million. This event is expected to have a high price impact (>=10%) based on the 12.6% volatility observed after the previous earnings report. This event is expected.
Eli Lilly reported Q1 2026 revenue of $19.8 billion (+56% YoY) and non-GAAP EPS of $8.55, beating estimates. The company raised its full-year 2026 revenue guidance to $82-$85 billion, driven by strong sales of Mounjaro and Zepbound. This significant growth and guidance raise is estimated to result in a >10% price impact.
The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.
Reported first-quarter 2026 results on 2026-04-30 and cut full-year 2026 outlook due to customer forecast updates and electrophysiology market dynamics; shares fell about 7.0% in premarket trading.
Board announced on 2026-04-30 that it had initiated a strategic review to maximize stockholder value, including evaluating a possible sale, merger, or strategic business combination; estimated medium positive impact because such reviews can create takeover optionality even though the same-day earnings release offset the reaction.
Signed a strategic cooperation agreement with DingTalk (an Alibaba company) to upgrade its operations with artificial intelligence applications. This operational partnership is estimated to have a low market impact (≥1%).
On April 30, 2026, the board of directors announced its proposal to appoint KPMG as the new auditor, replacing Ernst & Young, subject to shareholder approval. Importance is Low as auditor changes typically result in a minor market reaction of approximately 1%.
Announced that its SSS68 injection, a dual-target antibody for APRIL/BAFF, received IND approval from China's NMPA for three autoimmune disease indications; high importance estimated due to the significant clinical potential of the dual-target antibody in three indications, expected.
Alphabet announced Q1 2026 revenue of $109.9 billion (up 22% YoY) and EPS of $5.11 on 2026-04-29, significantly beating analyst estimates. Growth was driven by strong performance in Google Search and a 63% revenue increase in Google Cloud. A >10% price impact is estimated due to the significant earnings beat, expected.
On April 29, 2026, Medtronic received U.S. Food and Drug Administration (FDA) approval for its next-generation Mosaic Neo mitral valve and launched the device in the U.S.
Directors Tian Zhoushan and Li Dakui retired from the board on 2026-04-29; Low importance justified by minimal expected market impact from board personnel changes, scheduled.
Ex-dividend date for the 2025 final cash dividend of RMB 2 per 10 shares on April 29, 2026; approved at the AGM on April 16, 2026. The dividend amount suggests a >=1% price impact scheduled.
Announced Q1 2026 product revenue exceeded RMB 3.8 billion, a year-over-year increase of over 50%, driven by strong performance of its oncology and general biomedicine portfolios. The stock rose over 4.5% on the news.
Received two clinical trial approvals from China's NMPA for its self-developed Class 1 innovative drug, HS-10522 tablets, for the treatment of uncontrolled hypertension and primary aldosteronism.
The B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 was granted Breakthrough Therapy Designation by China's NMPA for the treatment of advanced castration-resistant prostate cancer.
Announced Q1 2026 results on April 28, 2026, with revenue of RMB 10.07 billion (+6.93% YoY) and net profit attributable to shareholders of RMB 871 million (+13.87% YoY). The 13.87% profit growth is estimated to result in a price impact of at least 10% expected.
Q1 2026 earnings release: revenue CNY 1.801 billion (+15.17% YoY), net profit CNY 49.04 million (-70.36% YoY); the 70% profit drop is estimated to cause a >10% price impact expected.
Announced Q1 2026 results, reporting revenue of CNY 656.2 million (+24.8% YoY) and a net profit of CNY 328 million, a swing to profitability from a loss of CNY 254 million in Q1 2025; high impact expected due to significant financial turnaround.
China's CDE proposed including IBI363, a first-in-class PD-1/IL-2α bispecific antibody, for breakthrough therapy designation for the treatment of advanced MSS/pMMR colorectal cancer. This regulatory progress is estimated to have a medium market impact (≥5%).
Released Q1 2026 earnings on 2026-04-28, with revenue up 15.5% YoY to RMB 3.58 billion and net profit up 9.75% YoY; strong order growth justifies an estimated 5% price impact.
Ivonescimab (PD-1/VEGF bispecific antibody) received multiple Class I recommendations in the 2026 Chinese Society of Clinical Oncology (CSCO) Guideline for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) on 2026-04-28. Market impact is estimated at Medium because of the drug's significant role in the first-line NSCLC market.
Received U.S. FDA clearance and CE Mark approval for Ultreon 3.0 Software, an AI-powered coronary imaging platform, on April 28, 2026.
Q1 2026 results: revenue +45.1% (RMB 726M), net loss narrowed 91.2%, non-GAAP profit achieved; high importance estimated as significant financial improvement is likely to cause a >10% price impact expected.
Reported strong Q1 2026 financial results on April 27, 2026, with revenue of CNY 12.44 billion (+28.8% YoY) and adjusted non-IFRS net profit of CNY 4.60 billion (+71.7% YoY), beating expectations and causing a significant share price increase.
Announced unaudited Q1 2026 financials for subsidiary CSPC Innovation on 2026-04-27, showing a 40.82% revenue increase but a 248.88% widening of net loss; a ~5% price impact is estimated due to mixed subsidiary performance.
Asymchem announced its Q1 2026 results on April 27, 2026, reporting a 16.91% YoY revenue increase to RMB 1.802 billion and a 6.82% net profit decrease to RMB 3.04 billion; a 5% price impact is estimated due to mixed results, expected.
On April 27, 2026, the FDA granted Priority Review for IMAAVY (nipocalimab) for the treatment of warm autoimmune hemolytic anemia (wAIHA), a rare blood disorder.
Positive preliminary clinical results for JS207 (PD-1/VEGF) and JS212 (EGFR/HER3) at 2026 AACR; medium importance estimated as clinical progress is likely to cause a 5-10% price impact scheduled.
Presented positive results from the AVANT GUARD clinical trial at the Heart Rhythm 2026 conference, showing its FARAPULSE Pulsed Field Ablation (PFA) system was superior to drug therapy for persistent atrial fibrillation (Medium importance estimated based on clinical significance); scheduled.
On April 24, 2026, the company disclosed that an unauthorized third party had accessed data in some of its IT systems. Medtronic stated it does not expect the incident to have a material impact on its business or financial results.
Announced on 2026-04-24 that its high-selectivity KAT6 inhibitor (SYH2095 tablet) received FDA IND approval; a ~1% price impact is estimated as this is an early-stage regulatory milestone.
Asymchem announced an agreement with the Tianjin Economic-Technological Development Area (TEDA) on April 24, 2026, to invest RMB 2 billion in expanding its CDMO R&D and production base; a 1% price impact is estimated, expected.